TRIBUTE : a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

収録刊行物

• J Clin Oncol

  J Clin Oncol 23 5892-5899, 2005